Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

Phase 4

Recruiting

Conditions: Crohn's Disease

Interventions: Drug: Vedolizumab
Drug: Adalimumab
Drug: Ustekinumab

First Posted Date: 2023-09-21

Last Posted Date: 2024-12-27

Lead Sponsor: Takeda

Target Recruit Count: 150

Registration Number: NCT06045754

Locations: 🇺🇸
Digestive Health Specialsits, Dothan, Alabama, United States
🇺🇸
GI Alliance Sun City, Sun City, Arizona, United States
🇺🇸
University of California San Diego Health (UCSD), La Jolla, California, United States

and more 50 locations

Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment

Phase 2

Recruiting

Conditions: Hunter Syndrome

Interventions: Drug: Idursulfase-IT
Drug: Elaprase

First Posted Date: 2023-09-11

Last Posted Date: 2024-04-04

Lead Sponsor: Takeda

Target Recruit Count: 8

Registration Number: NCT06031259

Locations: 🇨🇦
M.A.G.I.C. Clinic, Calgary, Alberta, Canada
🇨🇦
University of British Columbia, Vancouver, British Columbia, Canada
🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada

and more 1 locations

A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: TAK-279
Drug: Erythromycin
Drug: Phenytoin
Drug: Efavirenz

First Posted Date: 2023-08-16

Last Posted Date: 2024-02-06

Lead Sponsor: Takeda

Target Recruit Count: 172

Registration Number: NCT05995249

Locations: 🇺🇸
Celerion - Tempe, AZ Site, Tempe, Arizona, United States

A Study of TAK-279 in Adults With or Without Kidney Problems

Phase 1

Completed

Conditions: Healthy Volunteers
Renal Impairment

Interventions: Drug: TAK-279

First Posted Date: 2023-08-15

Last Posted Date: 2024-06-27

Lead Sponsor: Takeda

Target Recruit Count: 24

Registration Number: NCT05992155

Locations: 🇺🇸
Research by Design, Chicago, Illinois, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States

A Study to Gather Information About Overall Occurrence and New Cases of Dravet and Lennox-Gastaut Syndromes in Children, Teenagers and Adults in Spain

Recruiting

Conditions: Dravet Syndrome (DS)
Lennox-Gastaut Syndrome (LGS)

Interventions: Other: No intervention

First Posted Date: 2023-08-09

Last Posted Date: 2024-07-30

Lead Sponsor: Takeda

Target Recruit Count: 250

Registration Number: NCT05982717

Locations: 🇪🇸
Complejo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain
🇪🇸
H. Universitario Infantil Niño Jesús, Madrid, Spain
🇪🇸
H. Universitario La Paz, Madrid, Spain

and more 1 locations

A Study of TAK-279 in Adults With or Without Liver Damage

Phase 1

Completed

Conditions: Hepatic Impairment
Healthy Volunteers

Interventions: Drug: TAK-279

First Posted Date: 2023-08-04

Last Posted Date: 2024-08-29

Lead Sponsor: Takeda

Target Recruit Count: 27

Registration Number: NCT05976321

Locations: 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
American Research Corporation - Texas Liver Institute, San Antonio, Texas, United States

and more 1 locations

An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumors

Interventions: Drug: [14C] Subasumstat
Drug: Subasumstat

First Posted Date: 2023-08-04

Last Posted Date: 2024-08-06

Lead Sponsor: Takeda

Target Recruit Count: 3

Registration Number: NCT05976334

Locations: 🇭🇺
Central Hospital of Northern Pest - Military Hospital, Budapest, Hungary
🇭🇺
Pharmaceutical Research Associates Magyarorszag, Budapest, Hungary

A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Tablet Treatment and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment in Participants With Depression

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: SSRI
Drug: Vortioxetine Tablet

First Posted Date: 2023-07-06

Last Posted Date: 2024-08-02

Lead Sponsor: Takeda

Target Recruit Count: 147777

Registration Number: NCT05932407

Locations: 🇯🇵
Takeda selected site, Tokyo, Japan

A Study of Maribavir Pediatric Formulation in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Maribavir Commercial Tablet Formulation
Drug: Maribavir Pediatric Powder-for-oral Suspension Formulation
Drug: Rabeprazole

First Posted Date: 2023-06-26

Last Posted Date: 2023-09-21

Lead Sponsor: Takeda

Target Recruit Count: 32

Registration Number: NCT05918822

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease

Phase 3

Active, not recruiting

Conditions: Alpha1-Antitrypsin Deficiency

Interventions: Drug: Fazirsiran Injection

First Posted Date: 2023-06-12

Last Posted Date: 2024-10-16

Lead Sponsor: Takeda

Target Recruit Count: 37

Registration Number: NCT05899673

Locations: 🇺🇸
UF Clinical and Translational Science Institute, Gainesville, Florida, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
UAB Hospital Clinical Research Unit, Birmingham, Alabama, United States

and more 9 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy